Adaptive Biotechnologies Corp.

Today, FDA’s Oncologic Drugs Advisory Committee voted unanimously (12/12) in favor of the use of MRD as an endpoint to support accelerated approval of new therapies for patients with multiple myeloma. This is fantastic news for the hematology community, with the potential to bring life-saving therapies to patients sooner. https://lnkd.in/gkTUhEEq

It’s easy to understand why people diagnosed with lymphoma say they often experience emotional effects related to their lymphoma. This World Lymphoma Day let’s bring awareness to the important role of opening up about these feelings. Having honest conversations can help facilitate and empower patients in shared decision-making and connect the community to crucial resources. Learn more: https://lnkd.in/gzVSU3VP #WLAD2024 #Oncology

At this year's ASCO and EHA meetings, a multitude of clinical trial data and real-world evidence underscored the clinical benefit of specific and sensitive MRD assessment. Read our summary: https://lnkd.in/gdtSDJsS

During Blood Cancer Awareness Month, we join the blood cancer community in raising awareness and supporting those affected. We're proud to continue our partnership with the CLL Society, The Leukemia & Lymphoma Society, Lymphoma Research Foundation, Multiple Myeloma Research Foundation - MMRF, International Myeloma Foundation and HealthTree Foundation as we work toward our shared mission of improving the lives of those living with blood cancers. #BloodCancerAwarenessMonth #Oncology

Adaptive announces clonoSEQ IVDR certification, the first CE-marked MRD test to meet this standard. https://lnkd.in/gujEt5c3 FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Review the FDA-cleared uses of clonoSEQ: https://rb.gy/8tju9y

Susan Bobulsky, chief commercial officer, MRD at Adaptive was interviewed by Inside Precision Medicine discussing the benefit of MRD testing using clonoSEQ and how it can change the existing treatment paradigm for certain blood cancers. Read more: https://lnkd.in/gSsd6Jba

Using MRD as a primary endpoint in accelerated approval clinical trials for multiple myeloma has great potential to provide patients with access to new and novel therapies faster than ever before! https://lnkd.in/g4ZpEps7

Today was one of those days at Adaptive Biotechnologies Corp. that is full of fun, food, and #fundraising. Monster Dogs #seattle set up on the rooftop patio. Adapters enjoyed the food, the sunshine, great music, and each other’s company. Best of all, we raised money for cancer research with Fred Hutch Obliteride - everybody wins! #BeAdaptive

On June 30, Adaptive employees braved the threat of rain to join the Seattle community in the Defeat Multiple Myeloma Run/Walk. It was an incredible event and great opportunity to raise funds for immunotherapy research at the Fred Hutch Cancer Research Center.

As June comes to a close, we take a moment to reflect on the significance of Pride Month. It's a time for the LGBTQ+ community to shine and for allies to gain insight into the diverse experiences and challenges faced by its members. At Adaptive, we are dedicated to fostering a strong sense of community and belonging through education, advocacy, and celebrations. Read more: https://lnkd.in/g5RrpcRV